A recent study reported that long-term AMPK activation has adverse metabolic consequences, such as hyperphagia, obesity, and impaired insulin secretion, eliciting a caution for identifying AMPK activators [43]. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.